SEL 018
Alternative Names: IdeZork (Xork); IgG protease - Cartesian Therapeutics; SEL-018; Xork; Xork IgG ProteaseLatest Information Update: 05 Dec 2023
Price :
$50 *
At a glance
- Originator Selecta Biosciences
- Developer Cartesian Therapeutics
- Class Peptide hydrolases
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Glycogen storage disease type II
Most Recent Events
- 23 Aug 2023 SEL 018 is available for licensing as of 17 Aug 2023
- 09 Jan 2023 Astellas Pharma in-licenses SEL 018 from Selecta Biosciences for development in Pompe disease
- 03 Nov 2022 SEL 018 is available for licensing as of 03 Nov 2022. https://selectabio.com/portfolio/#pipeline (Selecta Biosciences pipeline, November 2022)